| Signature Health Services | |
| 606 Rollingbrook Drive Suite 2f, Baytown, Texas 77521 | |
| (281) 837-1321 | |
| Name | Signature Health Services |
|---|---|
| Location | 606 Rollingbrook Drive Suite 2f, Baytown, Texas |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 678499 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 77004, 77005, 77007, 77008, 77009, 77011, 77012, 77013, 77014, 77015, 77016, 77017, 77020, 77021, 77022, 77023, 77026, 77028, 77029, 77031, 77033, 77034, 77035, 77036, 77039, 77040, 77041, 77044, 77045, 77047, 77048, 77049, 77051, 77053, 77057, 77058, 77059, 77060, 77061, 77062, 77064, 77065, 77066, 77067, 77068, 77069, 77070, 77071, 77072, 77073, 77075, 77076, 77078, 77079, 77080, 77082, 77084, 77086, 77087, 77088, 77089, 77090, 77091, 77092, 77093, 77095, 77098, 77099, 77301, 77302, 77304, 77327, 77328, 77336, 77338, 77339, 77346, 77354, 77357, 77365, 77373, 77375, 77377, 77379, 77380, 77381, 77382, 77384, 77386, 77396, 77429, 77433, 77449, 77450, 77459, 77479, 77489, 77493, 77494, 77502, 77503, 77504, 77505, 77506, 77510, 77511, 77514, 77518, 77519, 77520, 77521, 77523, 77530, 77532, 77535, 77536, 77539, 77545, 77546, 77550, 77551, 77554, 77561, 77562, 77563, 77564, 77565, 77568, 77571, 77573, 77575, 77581, 77582, 77583, 77584, 77586, 77587, 77590, 77591, 77598, 77650, 77665 |
| NPI Number | 1548319288 |
| Organization Name | IMMANUEL HOME HEALTH CARE INC |
| Doing Business As | SIGNATURE HEALTH SERVICES |
| Address | 606 Rollingbrook, Suite 2f, Baytown, TX 77521 |
| Phone Number | 281-837-1321 |
News Archive
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Laboratories' U.S. Patents.
A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.
› Verified 4 days ago
| Quality Rating: |
News Archive
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Laboratories' U.S. Patents.
A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 98.6 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 98.8 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.9 | 99.6 |
| How often the home health team checked patients for depression | 99.8 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 77.9 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 85.3 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99.5 | 96.4 |
News Archive
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Laboratories' U.S. Patents.
A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 88.6 | 79.6 |
| How often patients got better at getting in and out of bed | 84.1 | 81.1 |
| How often patients got better at bathing | 93.2 | 82.3 |
| How often patients’ breathing improved | 88.7 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 91.2 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 87.7 | 75 |
| How often home health patients had to be admitted to the hospital | 13.5 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 14.2 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 92.7 | 94 |
News Archive
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Laboratories' U.S. Patents.
A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.
› Verified 4 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Laboratories' U.S. Patents.
A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.
› Verified 4 days ago
The patient survey data of Signature Health Services is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 90 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 88 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 85 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 85 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 82 | 78 |
News Archive
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Laboratories' U.S. Patents.
A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.
› Verified 4 days ago
Tender Home Health Care Inc Location: 407 W Baker Rd Ste S, Baytown, Texas 77521 Ratings: NA Phone: (281) 428-2807 | |
Nursing And Beyond Home Health Location: 2802 Garth Road Suite #315, Baytown, Texas 77521 Ratings: Phone: (281) 713-8674 | |
Signature Health Services Location: 606 Rollingbrook Drive Suite 2f, Baytown, Texas 77521 Ratings: Phone: (281) 837-1321 | |
Bay View Home Health Services Location: 7714 A Hwy 146, Baytown, Texas 77523 Ratings: Phone: (281) 573-7000 | |
Sev Home Care Inc Location: 4000 Garth Rd Ste 130, Baytown, Texas 77521 Ratings: Phone: (281) 420-1427 | |
Life Source Home Healthcare Inc Location: 3302 Garth Rd, Baytown, Texas 77521 Ratings: Phone: (281) 420-3977 |